Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients
- PMID: 39073825
- DOI: 10.1093/jac/dkae234
Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients
Comment in
-
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-authors' response.J Antimicrob Chemother. 2024 Dec 2;79(12):3360-3361. doi: 10.1093/jac/dkae357. J Antimicrob Chemother. 2024. PMID: 39373636 No abstract available.
Comment on
-
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.J Antimicrob Chemother. 2024 May 2;79(5):1196-1200. doi: 10.1093/jac/dkae082. J Antimicrob Chemother. 2024. PMID: 38538154 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
